临床微生物学市场－全球产业规模、份额、趋势、机会及预测（依产品、疾病、地区及竞争格局划分，2021-2031年）

全球临床微生物学市场预计将从 2025 年的 54.7 亿美元成长到 2031 年的 73.8 亿美元，复合年增长率为 5.12%。

该领域的核心重点是针对病原微生物（包括细菌、病毒、真菌和寄生虫）进行专业检测，以确保感染疾病的准确诊断和治疗。推动此领域发展的主要因素是感染疾病的上升趋势，以及快速诊断结果对于改善急诊护理中患者照护的重要性日益凸显。此外，自动化设备和分子诊断技术的应用提高了检查室效率，实现了现代医疗系统所需的高通量处理，为先进试剂和设备的应用创造了有利条件。

然而，市场面临着一个重大障碍，即合格的实验室专业严重短缺，而这些专业人员对于监督复杂的诊断工作流程至关重要。人才短缺造成了检测瓶颈，并限制了医疗机构采用新技术的能力。美国临床病理学会2024年的职缺调查显示，17个实验室专业中有10个专业的员工流动率正在上升，凸显了问题的严重性。这进一步加剧了支持市场持续扩张所需的技能人才短缺问题。

市场驱动因素

全球感染疾病和流行病的日益普及是临床微生物市场的主要驱动力，也迫切需要扩大诊断能力。随着病原体在各地传播的加剧，医疗卫生系统被要求升级其检查室基础设施，以应对不断增长的患者数量并确保严格的感染控制措施。日益加重的疾病负担意味着诊断耗材和设备的使用量增加，因为准确识别对于有效治疗至关重要。例如，根据世界卫生组织（世卫组织）发布的《2024年全球结核病报告》，预计2023年全球新增结核病病例将达到约820万例，这将是自1995年开始全球监测以来的最高数字，凸显了对强大的微生物学服务的迫切需求。

同时，分子诊断技术的进步正在改变市场模式，它能够快速、高通量地鑑定病原体，避免了传统培养方法带来的延误。检查室越来越多地使用自动化综合征检测平台，这些平台可在数小时内提供可操作的结果，这对复杂的感染疾病管理和药物管理专案至关重要。这一趋势反映在该行业的强劲表现中，生物梅里埃公司发布的《2024年第三季业务回顾》显示，非呼吸系统专科分子检测组合的销售额增长了18%。此外，应对抗菌素抗药性的迫切性也推动了这一趋势，健康指标与评估研究所（IHME）2024年的预测也证实了这一点。如果不采取行动，抗菌素抗药性可能导致2025年至2050年间全球超过3,900万人死亡。

市场挑战

全球临床微生物学市场面临的一大障碍是合格实验室专业（包括熟练的微生物学家和临床实验室技术人员）的严重短缺。这种人才短缺严重限制了诊断机构的运作能力，并在检测流程中造成了显着的瓶颈。随着医疗系统努力应对日益增长的检体量，人才不足导致检体处理和诊断结果发布延迟。因此，检查室往往被迫限制检测项目或延后采用需要专业监管的先进分子和自动化技术，减缓了这些重要创新技术的普及应用。

这种限制的严重性在招聘困难中显而易见；美国临床病理学会2025年报告称，实验室技术人员的招聘流程显着延长。该学会指出，许多科室需要三到十二个月的时间才能填补空缺，这种延误扰乱了实验室运作的连续性，并阻碍了服务根据需求进行扩展。最终，劳动力短缺限制了临床微生物产品的潜在市场，因为人手不足的检查室很难证明购买新设备或扩充试剂库存的资本支出是合理的，毕竟没有足够的人员来操作这些设备。

市场趋势

透过先进的就地检验设备实现诊断服务的去中心化，正在改变临床微生物学，将复杂的分子检测从中心检查室转移到更靠近患者的场所。这项转变的驱动力在于缩短严重感染疾病检测结果的等待时间，并使临床医生能够立即做出基于循证医学的治疗选择，而无需等待批量检测结果。製造商正在透过紧凑型、全自动平台来满足这一需求，这些平台可在几分钟内提供检查室层级的分子检测结果。生物梅里埃公司于2025年3月发布的「2024年财务业绩」印证了这一快速普及的趋势，该业绩显示，其SPOTFIRE照护现场解决方案的销售额达到约9500万欧元，超过了年度目标，并且全球安装量达到3000台。

同时，利用次世代定序（NGS）技术的基因组监测和总体基因体学正从小众研究领域走向常规临床实践。与针对特定病原体的传统方法不同，NGS可在单次运行中提供对新型菌株的无偏鑑定和全面的抗菌药物抗药性谱分析，这对于追踪医院感染爆发和管理复杂感染疾病至关重要。对这项技术的日益依赖也体现在财务业绩：2025年9月，牛津奈米孔技术公司公布其临床市场部门上半年收入按外汇汇率计算增长了52.9%，这表明纳米孔定序正迅速融入诊断工作流程。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球临床微生物学市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 副产品（测试设备、自动化培养系统、试剂等）
  • 依疾病分类（呼吸系统疾病、血液感染疾病、消化系统疾病、性行为感染、尿道感染、牙周病、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美临床微生物学市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲临床微生物学市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区临床微生物学市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲临床微生物学市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲临床微生物学市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球临床微生物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• bioMerieux SA
• Becton, Dickinson and Company
• Danaher Corporation
• Abbott Laboratories Inc.
• Hologic, Inc.
• F. Hoffmann-La Roche Ltd
• Bruker Corporation
• Bio-Rad Laboratories, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Clinical Microbiology Market is projected to expand from USD 5.47 Billion in 2025 to USD 7.38 Billion by 2031, reflecting a compound annual growth rate of 5.12%. This sector centers on the specialized laboratory analysis of pathogenic microorganisms-including bacteria, viruses, fungi, and parasites-to ensure accurate diagnosis and treatment of infectious diseases. Growth is largely driven by the rising burden of infectious conditions and the critical need for rapid diagnostic outcomes to improve patient care in acute settings. Additionally, the adoption of automated instrumentation and molecular diagnostic technologies enhances laboratory efficiency, enabling the high-throughput processing required by modern healthcare systems and fostering a favorable environment for advanced reagents and instruments.

However, the market encounters a substantial obstacle in the form of a severe shortage of qualified laboratory professionals needed to oversee complex diagnostic workflows. This gap in the workforce generates testing bottlenecks and restricts the ability of healthcare facilities to implement new technologies. Highlighting the severity of this issue, the American Society for Clinical Pathology's 2024 vacancy survey revealed that retirement rates had risen in ten out of seventeen laboratory departments, further exacerbating the scarcity of skilled personnel required to support sustained market expansion.

Market Driver

The escalating global prevalence of infectious diseases and epidemics acts as a major driver for the clinical microbiology market, necessitating an urgent expansion of diagnostic capabilities. As pathogen transmission increases across various regions, healthcare systems must upgrade their laboratory infrastructure to handle growing patient volumes and enforce strict infection control measures. This rise in disease burden leads to higher usage of diagnostic consumables and instruments, as accurate identification is essential for effective treatment. For instance, the World Health Organization's "Global Tuberculosis Report 2024" noted that approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, the highest number since global monitoring began in 1995, underscoring the critical need for robust microbiology services.

Concurrently, technological strides in molecular diagnostics are transforming the market by facilitating rapid, high-throughput pathogen identification that avoids the delays of traditional culture methods. Laboratories are increasingly utilizing automated syndromic testing platforms to provide actionable results in hours, a shift that is vital for managing complex infections and stewardship programs. This trend is reflected in strong industry performance; bioMerieux's "Third-Quarter 2024 Business Review" reported an 18% sales increase for specialized non-respiratory molecular panels. Furthermore, the urgency to combat antimicrobial resistance drives this adoption, as evidenced by Institute for Health Metrics and Evaluation forecasts in 2024, which predicted that without intervention, antimicrobial resistance could cause over 39 million deaths globally between 2025 and 2050.

Market Challenge

A primary hurdle impeding the Global Clinical Microbiology Market is the acute shortage of qualified laboratory professionals, including skilled microbiologists and medical laboratory scientists. This workforce scarcity severely constrains the operational capabilities of diagnostic facilities, causing substantial bottlenecks in testing workflows. As healthcare systems attempt to manage rising specimen volumes, the insufficient workforce delays sample processing and the release of diagnostic results. Consequently, laboratories often have to limit their test menus or postpone the adoption of advanced molecular and automated technologies that demand specialized supervision, thereby slowing the uptake of these critical innovations.

The severity of this constraint is evident in recruitment difficulties; in 2025, the American Society for Clinical Pathology reported that hiring processes for laboratory staff have become significantly prolonged. The association noted that many departments now take between three months and a year to fill open positions, a delay that disrupts laboratory continuity and hinders the ability to scale services to meet demand. Ultimately, this labor deficit limits the addressable market for clinical microbiology products, as understaffed laboratories find it difficult to justify capital expenditures on new instrumentation or expanded reagent inventories without the personnel to operate them.

Market Trends

The decentralization of diagnostic services through advanced point-of-care testing devices is reshaping clinical microbiology by relocating complex molecular testing from central labs to near-patient environments. This transition is motivated by the need to shorten turnaround times for critical infections, allowing clinicians to make immediate, evidence-based treatment choices instead of waiting for batch-processed results. Manufacturers are meeting this demand with compact, fully automated platforms that provide laboratory-quality molecular results in minutes. This rapid adoption is illustrated by bioMerieux's "2024 Financial Results" from March 2025, which reported that sales for their SPOTFIRE point-of-care solution reached nearly €95 million, exceeding annual targets with a global installed base of 3,000 units.

In parallel, the application of Next-Generation Sequencing (NGS) for genomic surveillance and metagenomics is moving from niche research into routine clinical practice. Unlike traditional methods targeting specific pathogens, NGS provides an unbiased mechanism to identify novel strains and comprehensive antimicrobial resistance profiles in a single run, which is essential for tracking hospital-acquired outbreaks and managing complex infections. The increasing reliance on this technology is reflected in financial results; Oxford Nanopore Technologies reported in September 2025 that revenue in their clinical market segment rose by 52.9% on a constant currency basis for the first half of the year, highlighting the swift integration of nanopore sequencing into diagnostic workflows.

Key Market Players

• bioMerieux SA
• Becton, Dickinson and Company
• Danaher Corporation
• Abbott Laboratories Inc.
• Hologic, Inc.
• F. Hoffmann-La Roche Ltd
• Bruker Corporation
• Bio-Rad Laboratories, Inc.

Report Scope

In this report, the Global Clinical Microbiology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clinical Microbiology Market, By Product

• Laboratory Instruments
• Automated Culture System
• Reagents
• Others

Clinical Microbiology Market, By Disease

• Respiratory Diseases
• Bloodstream Infection
• Gastrointestinal Diseases
• Sexually Transmitted Diseases (STDs)
• Urinary Tract Infections
• Periodontal Diseases
• Others

Clinical Microbiology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clinical Microbiology Market.

Available Customizations:

Global Clinical Microbiology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Clinical Microbiology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Laboratory Instruments, Automated Culture System, Reagents, Others)
  • 5.2.2. By Disease (Respiratory Diseases, Bloodstream Infection, Gastrointestinal Diseases, Sexually Transmitted Diseases (STDs), Urinary Tract Infections, Periodontal Diseases, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Clinical Microbiology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Disease
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Clinical Microbiology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Disease
  • 6.3.2. Canada Clinical Microbiology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Disease
  • 6.3.3. Mexico Clinical Microbiology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Disease

7. Europe Clinical Microbiology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Disease
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Clinical Microbiology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Disease
  • 7.3.2. France Clinical Microbiology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Disease
  • 7.3.3. United Kingdom Clinical Microbiology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Disease
  • 7.3.4. Italy Clinical Microbiology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Disease
  • 7.3.5. Spain Clinical Microbiology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Disease

8. Asia Pacific Clinical Microbiology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Disease
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Clinical Microbiology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Disease
  • 8.3.2. India Clinical Microbiology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Disease
  • 8.3.3. Japan Clinical Microbiology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Disease
  • 8.3.4. South Korea Clinical Microbiology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Disease
  • 8.3.5. Australia Clinical Microbiology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Disease

9. Middle East & Africa Clinical Microbiology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Disease
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Clinical Microbiology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Disease
  • 9.3.2. UAE Clinical Microbiology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Disease
  • 9.3.3. South Africa Clinical Microbiology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Disease

10. South America Clinical Microbiology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Disease
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Clinical Microbiology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Disease
  • 10.3.2. Colombia Clinical Microbiology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Disease
  • 10.3.3. Argentina Clinical Microbiology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Disease

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Clinical Microbiology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. bioMerieux SA
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Becton, Dickinson and Company
• 15.3. Danaher Corporation
• 15.4. Abbott Laboratories Inc.
• 15.5. Hologic, Inc.
• 15.6. F. Hoffmann-La Roche Ltd
• 15.7. Bruker Corporation
• 15.8. Bio-Rad Laboratories, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer